Analysts See $-0.19 EPS for Intec Pharma Ltd. (NTEC)

March 14, 2018 - By Richard Conner

 Analysts See $ 0.19 EPS for Intec Pharma Ltd. (NTEC)

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.19 EPS on April, 6.They anticipate $0.13 EPS change or 40.63 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Intec Pharma Ltd.’s analysts see -52.50 % EPS growth. The stock increased 0.77% or $0.05 during the last trading session, reaching $6.55. About 129,122 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 51.00% since March 14, 2017 and is uptrending. It has outperformed by 34.30% the S&P500.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Coverage

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Thursday, June 22 by Oppenheimer. The stock has “Buy” rating by Oppenheimer on Thursday, September 21. Roth Capital maintained the stock with “Buy” rating in Thursday, August 3 report. The firm earned “Buy” rating on Friday, September 11 by Roth Capital. The firm has “Buy” rating by Roth Capital given on Monday, July 24. The stock has “Buy” rating by Roth Capital on Thursday, August 10. The firm earned “Buy” rating on Thursday, November 16 by Oppenheimer. TH Capital initiated the shares of NTEC in report on Friday, September 11 with “Buy” rating. Maxim Group initiated the shares of NTEC in report on Wednesday, September 16 with “Buy” rating.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $157.65 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More notable recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: which released: “Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies” on March 22, 2017, also with their article: “Intec Pharma, Ltd. Announces Changes to its Board of Directors” published on November 01, 2017, Globes.Co.Il published: “Intec Pharma raising $57.5m on Nasdaq” on August 17, 2017. More interesting news about Intec Pharma Ltd. (NASDAQ:NTEC) were released by: and their article: “Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa …” published on March 12, 2018 as well as‘s news article titled: “Intec Pharma Names R. Michael Gendreau, MD, Ph.D. as Chief Medical Officer” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.